Type I interferonâ-mediated monogenic autoinflammation: The type i interferonopathies, a conceptual overview

Mathieu P. Rodero, Yanick J. Crow

Research output: Contribution to journalArticlepeer-review

Abstract

Type I interferon is a potent substance. As such, the induction, transmission, and resolution of the type I interferonâ-mediated immune response are tightly regulated. As defined, the type I interferonopathies represent discrete examples of a disturbance of the homeostatic control of this system caused by Mendelian mutations. Considering the complexity of the interferon response, the identification of further monogenic diseases belonging to this disease grouping seems likely, with the recognition of type I interferonopathies becoming of increasing clinical importance as treatment options are developed based on an understanding of disease pathology and innate immune signaling. Definition of the type I interferonopathies indicates that autoinflammation can be both interferon and noninterferon related, and that a primary disturbance of the innate immune system can spill over into autoimmunity in some cases. Indeed, that several non-Mendelian disorders, most particularly systemic lupus erythematosus and dermatomyositis, are also characterized by an up-regulation of type I interferon signaling suggests the possibility that insights derived from this work will have relevance to a broader field of clinical medicine.

Original languageEnglish
Pages (from-to)2527-2538
Number of pages12
JournalJournal of Experimental Medicine
Volume213
Issue number12
DOIs
Publication statusPublished - 7 Nov 2016

Fingerprint

Dive into the research topics of 'Type I interferonâ-mediated monogenic autoinflammation: The type i interferonopathies, a conceptual overview'. Together they form a unique fingerprint.

Cite this